AIM: The aim of this study is to evaluate the correlation between psoriasis and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This provides an important reference for formulating guidelines for the management of psoriasis comorbidities and improving the long-term prognosis of patients. METHODS: A systematic search was conducted across four databases: PubMed, Web of Science, Embase, and the Cochrane Library, covering the period from their inception to November 2025. A meta-analysis employing random-effects model (DerSimonian-Laird method) was conducted to assess the association between MASLD in psoriatic and non-psoriatic patients. Subgroup analyses were performed for psoriatic arthritis (PsA) and patients with moderate-to-severe psoriasis. RESULTS: This review included 13 studies comprising 6 case-control studies, 3 cohort studies, and 4 cross-sectional studies. Meta-analysis results indicated that individuals with psoriasis exhibited an increased risk of MASLD compared to those without psoriasis (OR=2.16, 95% CI: 1.65-2.83). Further subgroup analysis revealed that patients with moderate to severe psoriasis exhibited a heightened risk of MASLD compared to those with mild psoriasis (OR=2.81, 95% CI: 1.62-4.86). Additionally, the risk of MASLD among patients with PsA was not statistically significant (OR=1.48, 95% CI: 0.69-3.19). CONCLUSION: There is an association between psoriasis and MASLD, and patients with moderate to severe psoriasis have a higher risk of MASLD. Current evidence does not show a clear association between PsA and MASLD, but this conclusion is limited by the small number of included studies and requires further validation. This study provides a reference basis for formulating guidelines for the management of comorbidities in psoriasis, but it should be interpreted with caution due to the inherent limitations of observational studies.
Nie et al. (2026) studied this question.